Form 8-K - Current report:
SEC Accession No. 0001520138-21-000393
Filing Date
2021-08-05
Accepted
2021-08-05 16:25:52
Documents
13
Period of Report
2021-08-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT bivi-20210805_8k.htm   iXBRL 8-K 37240
2 EXHIBIT 99.1 bivi-20210805_8kex99z1.htm EX-99.1 13534
  Complete submission text file 0001520138-21-000393.txt   229022

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bivi-20210805.xsd EX-101.SCH 3044
4 XBRL LABEL FILE bivi-20210805_lab.xml EX-101.LAB 34238
5 XBRL PRESENTATION FILE bivi-20210805_pre.xml EX-101.PRE 22371
6 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20210805_8k_htm.xml XML 3585
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

EIN.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39015 | Film No.: 211148676
SIC: 2834 Pharmaceutical Preparations